Search - tctmd.com

Displaying 61 - 80 of 292

Sort: Relevancy | Date

Presentation TVT 2023

The Stroke Issue and When to Consider Cerebral Embolic Protection Devices (CEPD)

Presenter: Tamim Nazif

June 07, 2023

News Conference News EuroPCR 2023

Flushing TAVI Valves With Carbon Dioxide May Protect Against Brain Injury

Todd Neale

May 16, 2023

News Daily News

Top Structural Heart News of 2022

L.A. McKeown

January 06, 2023

News Opinion Editor's Corner

The Biggest News of 2022: TCTMD’s Top 10

Shelley Wood

December 30, 2022

News Features

Prudence or Spin? Mulling Embolic Protection After PROTECTED TAVR

Todd Neale

October 17, 2022

News Conference News TCT 2022

Mix of Patient, Procedural, and Device Factors All Drove TAVI Advances

Caitlin E. Cox

September 19, 2022

Presentation TCT 2022

TCT 333: Effect of stroke on readmissions and cardiovascularoutcomes in patients with Mitraclip.

Presenter: Nirav Patel

September 19, 2022

Presentation TCT 2022

TCT 332: Clinical outcome of transcatheter aortic valve replacement with TriGUARD 3™ cerebral embolic protection device

Presenter: Sayonara Daal

September 19, 2022

Presentation TCT 2022

TCT 331: Predictors of Valvular and Perivalvular Thrombosis and Relations of Neurological Outcomes after TAVR: ADAPT-TAVR Substudy

Presenter: Yeonwoo Choi

September 19, 2022

Presentation TCT 2022

TCT 329: Cerebral Embolic Protection Devices For Prevention Of Post-Procedural Ischemic Stroke With Transcatheter Aortic Valve Replacement: A SYSTEMATIC REVIEW AND META-ANALYSIS

Presenter: Tanesh Ayyalu

September 18, 2022

Presentation TCT 2022

TCT 328: Low-dose or Standard-dose Edoxaban versus Dual Antiplatelet Therapy for Leaflet Thrombus and Cerebral Thromboembolism after Transcatheter Aortic Valve Replacement (TAVR): Subgroup Analysis of the Randomized ADAPT-TAVR Trial

Presenter: Mijin Kim

September 18, 2022

Presentation TCT 2022

TCT 327: Clinical and Radiographic Measures of Stroke-Related Outcomes with Cerebral Embolic Protection Devices During TAVR: A Meta-analysis.

Presenter: Arpanjeet Kaur

September 18, 2022

Presentation TCT 2022

Regulatory Pathways and Clinical Trials After PROTECTED TAVR

Presenter: Alexandra J. Lansky

September 17, 2022

Presentation TCT 2022

New and Novel CEP Devices: Differentiating Features

Presenter: Giora Weisz

September 17, 2022

Presentation TCT 2022

None Use: The Data Are Unconvincing and the Cost Is Prohibitive

Presenter: David J. Cohen

September 17, 2022

Presentation TCT 2022

Selective Use: Only in Vulnerable Patients

Presenter: John K. Forrest

September 17, 2022

Presentation TCT 2022

Systematic Use: Unravelling the Stroke Story

Presenter: Nicolas M. Van Mieghem

September 17, 2022

Presentation TCT 2022

The British Heart Foundation PROTECT TAVI Trial: The Next Round!

Presenter: Daniel J. Blackman

September 17, 2022

Presentation TCT 2022

Other Registry Findings and PROTECTED TAVR: Concordant or Divergent

Presenter: Raj Makkar

September 17, 2022

Presentation TCT 2022

The Journey of CEP from Clean TAVI to PROTECTED TAVR: Lessons Learned

Presenter: Axel Linke

September 17, 2022

Advertisement

The Stroke Issue and When to Consider Cerebral Embolic Protection Devices (CEPD)

Flushing TAVI Valves With Carbon Dioxide May Protect Against Brain Injury

Top Structural Heart News of 2022

The Biggest News of 2022: TCTMD’s Top 10

Prudence or Spin? Mulling Embolic Protection After PROTECTED TAVR

Mix of Patient, Procedural, and Device Factors All Drove TAVI Advances

TCT 333: Effect of stroke on readmissions and cardiovascularoutcomes in patients with Mitraclip.

TCT 332: Clinical outcome of transcatheter aortic valve replacement with TriGUARD 3™ cerebral embolic protection device

TCT 331: Predictors of Valvular and Perivalvular Thrombosis and Relations of Neurological Outcomes after TAVR: ADAPT-TAVR Substudy

TCT 329: Cerebral Embolic Protection Devices For Prevention Of Post-Procedural Ischemic Stroke With Transcatheter Aortic Valve Replacement: A SYSTEMATIC REVIEW AND META-ANALYSIS

TCT 328: Low-dose or Standard-dose Edoxaban versus Dual Antiplatelet Therapy for Leaflet Thrombus and Cerebral Thromboembolism after Transcatheter Aortic Valve Replacement (TAVR): Subgroup Analysis of the Randomized ADAPT-TAVR Trial

TCT 327: Clinical and Radiographic Measures of Stroke-Related Outcomes with Cerebral Embolic Protection Devices During TAVR: A Meta-analysis.

Regulatory Pathways and Clinical Trials After PROTECTED TAVR

New and Novel CEP Devices: Differentiating Features

None Use: The Data Are Unconvincing and the Cost Is Prohibitive

Selective Use: Only in Vulnerable Patients

Systematic Use: Unravelling the Stroke Story

The British Heart Foundation PROTECT TAVI Trial: The Next Round!

Other Registry Findings and PROTECTED TAVR: Concordant or Divergent

The Journey of CEP from Clean TAVI to PROTECTED TAVR: Lessons Learned

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content